Theravance Biopharma holds 2025 annual meeting, elects directors, ratifies auditor, approves say-on-pay

Theravance Biopharma, Inc.

Shareholders elected Rick E. Winningham, Jeremy T. Grant, Susannah Gray, Donal O'Connor as Class II directors.
Ratification of Ernst & Young as auditor for FY2025 approved: 45,165,816 for, 578,070 against.
Advisory say-on-pay resolution approved: 30,154,992 for, 374,257 against, 9,536,311 abstain.
Quorum of 45,746,079 shares (91.5% outstanding) present at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.